Novel Post-Translational Modification Learning Signature Reveals B4GALT2 as an Immune Exclusion Regulator in Lung Adenocarcinoma

The identification of B4GALT2 as a previously unrecognized oncogenic factor involved in immune exclusion presents a novel therapeutic avenue for LUAD treatment and immunotherapy optimization.